How to monitor eye health in a type 2 diabetic?

Question

Hello doctor,

I am a 63-year-old male with proliferative diabetic retinopathy (receiving regular anti-VEGF injections), type 2 diabetes mellitus (A1C 9.2 percent), and obesity (BMI (basal metabolic index) -37). I started compounded semaglutide three weeks ago. A recent eye exam shows stable retinopathy, but there are concerns about rapid glucose reduction. What is the recommended frequency of ophthalmological monitoring during GLP-1 receptor agonist therapy? Is there a specific A1C reduction rate we should target to minimize retinopathy progression? Should anti-VEGF treatment intervals be modified during the initial titration period?

Please help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

Recommended frequency of ophthalmological monitoring-

Baseline examination: Before initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, a comprehensive eye examination is recommended to establish a baseline.
Regular follow-ups: Schedule follow-up eye exams every three to six months during the initial treatment period (the first 6 to 12 months).
Stable patients: For patients with stable retinopathy, annual or bi-annual eye exams may be sufficient.

Target A1C(glycated hemoglobin) reduction rate-

1. Gradual A1C reduction: Aim for a gradual A1C reduction of 0.5 to 1.0 percent per month to minimize the risk of retinopathy progression.

2. Avoid rapid A1C reduction: Rapid A1C reduction (greater than 2.0 percent in three to six months) may increase the risk of retinopathy progression.

I hope this helps.

Kindly follow up if you have more concerns.

Thank you.